Statins And The Alzheimer’s Clock

Your medicine cabinet feels organized for a reason: we like to believe each pill has a single target and stays in its lane. Then we hit a finding that blows up that mental map. Millions of people take statins and other cholesterol drugs to manage LDL and cardiovascular risk, but a massive new dataset suggests those same lipid-lowering regimens may also slow Alzheimer’s disease decline, especially in the years when independence matters most. 

We walk through a 2026 study drawing on more than 28,000 participants followed for up to 15 years, and we explain why the first glance at the data looks scary. Statin users score worse at baseline on common cognitive tests, yet that’s the classic trap of confounding by indication: the people on the meds start out with higher vascular and metabolic risk. When the researchers focus on longitudinal change using a real-world functional scale, the trend flips. Small annual differences compound, lowering transition rates from mild cognitive impairment to dementia and slowing progression even in later stages. 

Then comes the twist: autopsy data shows no meaningful difference in classic Alzheimer’s pathology measures between users and non-users. That forces a new frame centered on systemic resilience. We connect vascular stabilization, anti-inflammatory effects, and a specific biochemical culprit: oxysterols like 27OHC that can cross the blood-brain barrier, overstimulate microglia, and accelerate neuroinflammation. We also dig into who sees the biggest benefits by age, sex, and APOE4 genetics, and we end with a provocative question about next-generation drugs designed to act inside the brain. Subscribe, share this with someone thinking about brain health, and leave a review with the question you want us to tackle next.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Transcript

Medicine Cabinet Myth About The Body

SPEAKER_00 0:00

So, um when you open your medicine cabinet every morning, you likely have this, you know, ingrained expectation of geography.

SPEAKER_01 0:09

Aaron Powell Oh, absolutely. You assume every little bottle has its own strictly assigned territory.

SPEAKER_00 0:13

Aaron Powell Right. Like the white pill works on your heart, the blue one goes to your lungs, and you know, never the twain shall meet.

SPEAKER_01 0:20

Yeah, which is a very compartmentalized way of thinking about human biology. I mean, it's completely understandable, but it's uh it's fundamentally inaccurate.

SPEAKER_00 0:28

Totally.

SPEAKER_01 0:29

Because the body is this immensely complex interconnected network. So a drug engineered for one specific organ is often quietly remodeling an entirely different system at the

Why Statins Could Matter For Alzheimer’s

SPEAKER_01 0:40

exact same time.

SPEAKER_00 0:40

Aaron Ross Powell, which is exactly why a medication millions of people take simply to lower their cholesterol might actually be um a critical key to slowing down Alzheimer's disease.

SPEAKER_01 0:50

Aaron Powell Yeah, it's a fascinating connection.

SPEAKER_00 0:52

Aaron Powell So today we're doing a deep dive for you into a massive new study published in 2026 in the Journal of Prevention of Alzheimer's disease.

SPEAKER_01 0:59

Right by Sternberg and colleagues.

SPEAKER_00 1:01

Aaron Powell Exactly. And our mission for this deep dive is to bridge that gap. We want to connect the everyday lipid lowering regimens, you know, standard statins and cholesterol drugs, with the actual physical architecture of the brain.

SPEAKER_01 1:14

Aaron Powell And I think what makes this research so definitive is the sheer scale of the data Sternberg's

Study Scale Plus Hidden Bias

SPEAKER_01 1:20

team utilized.

SPEAKER_00 1:21

Oh wow. Yeah, let's unpack that. Yeah. Because they didn't just look at a few hundred people over a semester or something.

SPEAKER_01 1:26

No, not at all. They pulled records for over 28,000 participants from the National Alzheimer's Coordinating Center.

SPEAKER_00 1:32

Aaron Powell That is massive.

SPEAKER_01 1:34

It really is. And they tracked these individuals for up to 15 years.

SPEAKER_00 1:38

Aaron Powell A decade and a half of tracking human lives. But you know, to get a clean signal from all that messy data, they had to be pretty ruthless with their filtering, right?

SPEAKER_01 1:47

Aaron Ross Powell They were incredibly ruthless. They ingeniously excluded anyone taking blood pressure or diabetes medications.

SPEAKER_00 1:52

Aaron Powell Wait, why just those two?

SPEAKER_01 1:54

Aaron Powell Well, we know hypertension and insulin resistance heavily influence cognitive decline on their own.

SPEAKER_00 1:59

Aaron Powell Ah, right. It muddies the waters.

SPEAKER_01 2:01

Aaron Ross Powell Exactly. So by removing participants on those specific treatments, the researchers essentially stripped away the overlapping noise.

SPEAKER_00 2:09

Aaron Powell Okay. So they isolated the exact independent effect of the cholesterol drugs to see what they were doing on their own.

SPEAKER_01 2:15

Aaron Powell That's it. But you know what's fascinating here is that the findings don't actually start with a triumph.

SPEAKER_00 2:21

Aaron Powell No, they really don't. In fact, if you just glance at the initial cross-sectional data like the day zero snapshot of all these participants, it creates a pretty alarming picture. Trevor Burrus, Jr.

SPEAKER_01 2:32

It does. It looks terrible at first glance.

SPEAKER_00 2:34

Aaron Powell Because the participants taking the cholesterol drugs were actually scoring worse on cognitive tests compared to the people not taking the medication.

SPEAKER_01 2:42

Trevor Burrus Right. The initial data showed significantly lower scores on the MOCA.

SPEAKER_00 2:46

That's the Montreal cognitive assessment.

SPEAKER_01 2:48

Yes, exactly. It's used to check short-term memory and uh visuospatial abilities. And they also scored lower on the MMSE.

SPEAKER_00 2:55

Aaron Powell The Mini Mental State Examination. Trevor Burrus, Jr.

SPEAKER_01 2:57

Right, which measures basic orientation and attention.

SPEAKER_00 2:59

Aaron Ross Powell So seeing that on a spreadsheet immediately triggers a bias. I mean you see a group of people taking a specific pill, and you see that they have worse memory scores.

SPEAKER_01 3:08

Aaron Powell Yeah. The instinct is to assume the medication is causing the decline.

SPEAKER_00 3:12

Aaron Powell Wait, so does that mean the medicine is compromising their cognition? I mean it's the classic logical fallacy of walking into a hospital, seeing rows of sick people in beds, and concluding that the hospital building itself is making them sick.

SPEAKER_01 3:27

Aaron Powell That's a great analogy. And that phenomenon is known in epidemiology as confounding by indication.

SPEAKER_00 3:33

Aaron Powell Confounding by Indication. Okay, break that down for us.

SPEAKER_01 3:36

Aaron Ross Powell Well, we have to look at the underlying reason these participants were prescribed lipid lowering regimens in the first place.

SPEAKER_00 3:42

Aaron Powell They got high cholesterol.

SPEAKER_01 3:43

Exactly. They had existing vascular issues. Their baseline cardiovascular and metabolic risk profiles were significantly worse than the control group.

SPEAKER_00 3:52

Aaron Powell So their underlying biology had already put them in the danger zone for cognitive decline long before the study even started.

SPEAKER_01 3:58

Aaron Powell Precisely. Chronic high cholesterol subtly damages the microvessels throughout the body. And that includes the tiny blood vessels supplying the brain. Right. So the people taking the medication were inherently more vulnerable to cognitive issues right from the start.

SPEAKER_00 4:14

Aaron Powell So that initial cross-sectional snapshot, it merely captures the reality that sicker people require more medication.

SPEAKER_01 4:21

Exactly. To strip away that bias, we have to look past the snapshot and analyze the longitudinal data over time. You know, the 10-year movie.

Long Term Data Flips The Story

SPEAKER_00 4:30

Okay, let's unpack that longitudinal data because the 10-year progression completely flips the script.

SPEAKER_01 4:35

It really does. It's a dramatic shift.

SPEAKER_00 4:37

Aaron Powell So the researchers tracked cognitive and functional decline using the CDR SOB. That's the clinical dementia rating sum of boxes.

SPEAKER_01 4:45

Aaron Powell Right, which is a scoring system that moves beyond just, you know, standard memory quizzes.

SPEAKER_00 4:49

Aaron Powell It measures real-world functional decline, right? Things like personal care, community affairs, and problem solving.

SPEAKER_01 4:55

Aaron Powell Yes, exactly. It's about how someone actually navigates their life. And for participants who started the study with mild cognitive impairment, the users of the cholesterol drugs experienced a noticeably slower rate of decline.

SPEAKER_00 5:08

Aaron Powell Okay, but let's look at the actual numbers. Because the data showed their yearly increase on that dementia severity scale was reduced by 0.0088 units compared to non-users.

SPEAKER_01 5:21

Aaron Powell That is what the data showed, yes.

SPEAKER_00 5:23

I have to play the skeptic here because mathematically, point zero zero zero eight eight sounds entirely negligible. I mean, why should you or I care about a fraction of a fraction of a point?

SPEAKER_01 5:33

I get that. It sounds tiny in a vacuum.

SPEAKER_00 5:36

Right. It's hard to see the practical value.

SPEAKER_01 5:38

But chronic neurodegeneration is a game of inches. You have to conceptualize this in the context of a progressive disease that currently has no definitive cure. Aaron Ross Powell, Jr.

SPEAKER_00 5:46

Buying time is the ultimate clinical goal.

SPEAKER_01 5:49

Exactly. Alzheimer's doesn't strip away independence overnight. It's a gradual cascading failure.

SPEAKER_00 5:54

Aaron Ross Powell So it's the physiological equivalent of compounding interest.

SPEAKER_01 5:57

That's a perfect way to look at it.

SPEAKER_00 5:58

Like if you shift an interest rate by a fraction of a percent when you open a retirement account, the difference year over year is invisible.

SPEAKER_01 6:05

Right. You don't notice it in year one or two.

SPEAKER_00 6:07

But let that tiny mathematical change compound over a decade, and it creates a massive divergence in the final outcome.

SPEAKER_01 6:15

Aaron Powell And that divergence is clearly visible in the transition rates. So among those with mild cognitive impairment, only 1.48% of the cholesterol drug users transitioned into full-blown dementia per year.

SPEAKER_00 6:29

Compared to 1.83% of the non-users.

SPEAKER_01 6:32

Yes. And over 10 years, that fractional difference compounds into literally years of preserved daily function.

SPEAKER_00 6:40

Oh wow. So it represents the difference between an individual managing their own household versus requiring institutionalized round-the-clock care.

SPEAKER_01 6:49

Absolutely. It's the difference between living at home and being in a nursing facility.

SPEAKER_00 6:52

And the protection also held for people already suffering from advanced stages of the disease, didn't it?

SPEAKER_01 6:57

It did. For participants who had already progressed to dementia, the slowing effect was actually even more pronounced.

SPEAKER_00 7:03

Wait, really? Even in late stages?

SPEAKER_01 7:05

Yeah. Over a 10-year window, only 0.53% of the lipid-lowering drug users hit the severe final stage of dementia.

SPEAKER_00 7:13

Compared to 1.50% of the non-users, that is a massive relative difference.

SPEAKER_01 7:18

Aaron Powell It's huge. And over the full 15-year tracking period, the drug users simply survived significantly longer.

SPEAKER_00 7:24

Aaron Powell Okay, so we know the drugs by time, but do they via the same amount of time for everyone?

Age Genetics And Sex Differences

SPEAKER_01 7:30

That is a great question. And the demographic stratification of this data is where we find the real mechanical insights.

SPEAKER_00 7:36

Aaron Powell Because this protective effect was not universally distributed across the population.

SPEAKER_01 7:41

Rare. No, it wasn't. The age breakdown is particularly fascinating. Aaron Powell Yeah.

SPEAKER_00 7:45

The study showed the protective benefits only emerge in participants over the age of 50. Trevor Burrus, Jr.

SPEAKER_01 7:49

Right. If a participant was in their forties, the cholesterol drugs showed essentially no cognitive benefit whatsoever.

SPEAKER_00 7:55

Trevor Burrus And the protection was strongest for those over 70. Trevor Burrus, Jr.

SPEAKER_01 7:57

Which aligns perfectly with how cumulative biological damage works. I mean, a 40-year-old brain generally still has robust vascular defenses and neuroplasticity.

SPEAKER_00 8:06

Aaron Powell So the structural damage from poor lipid metabolism hasn't reached a critical threshold yet.

SPEAKER_01 8:12

Exactly. But by age 70, the cumulative vascular and metabolic stress is actively threatening the brain's defenses.

SPEAKER_00 8:19

So the medication is intervening exactly when the biological infrastructure begins to buckle.

SPEAKER_01 8:24

You hit the nail on the head. And then there is a genetic layer specifically regarding the APOE4 allele.

SPEAKER_00 8:30

Right. We've long known that carrying the APOE4 gene is one of the most significant risk factors for developing Alzheimer's.

SPEAKER_01 8:36

Yes, it's a major genetic red flag.

SPEAKER_00 8:38

And the study found that people with this specific genetic marker saw highly pronounced outsized benefits from taking these cholesterol drugs.

SPEAKER_01 8:46

To understand why, we have to look at what APOE4 actually does.

SPEAKER_00 8:50

Okay, lay it on this.

SPEAKER_01 8:51

So the APOE gene family produces apalipoprotein E. This is a protein that transports fats and cholesterol throughout the body and the brain. Right. But the E4 variant of this gene is structurally less efficient. It struggles to clear lipids, leading to cellular stress and inflammation.

SPEAKER_00 9:07

Wait, so the gene most famous for causing Alzheimer's, it's fundamentally a cholesterol management gene.

SPEAKER_01 9:12

Yes, exactly. If we connect this to the bigger picture, when a patient with that faulty E4 gene takes a lipid-lowering drug, the medication is actively reducing the overall peripheral cholesterol burden.

SPEAKER_00 9:25

Oh, I see. It is artificially managing the lipid load that the genetic mutation is failing to handle.

SPEAKER_01 9:31

Precisely. It provides direct support to the exact biological system, the APOE4 mutation compromises.

SPEAKER_00 9:38

So what does this all mean? It makes me think of putting premium fuel into a car engine.

SPEAKER_01 9:43

Oh, I like where this is going.

SPEAKER_00 9:45

Like if you have a brand new low-risk engine, say, a 40-year-old without the APOE4 gene paying for premium fuel doesn't noticeably change how the car dries.

SPEAKER_01 9:55

Right. The engine is already highly efficient.

SPEAKER_00 9:57

But if the engine is older, or if it has a faulty fuel injector that causes it to run hot, which is essentially what the APOE4 gene is doing, suddenly that premium fuel makes a massive difference in preventing a breakdown on the highway.

SPEAKER_01 10:08

That is a brilliant analogy. And taking that car analogy a step further, the researchers also uncovered distinct mechanical differences based on gender.

SPEAKER_00 10:16

Oh, right. For the transition phase, moving from mild cognitive impairment into early dementia men saw significant protective benefits from the medication while women did not.

SPEAKER_01 10:27

Yes, but only in that early transition phase.

SPEAKER_00 10:30

Because once the disease progressed into the later stages of dementia, both men and women benefited significantly.

SPEAKER_01 10:37

Right. And we think this is because hormonal environments uniquely influence lipid metabolism and vascular health.

SPEAKER_00 10:44

Like estrogen.

SPEAKER_01 10:45

Exactly. Estrogen offers distinct neuroprotective and vascular benefits early on. This might mask or alter the effectiveness of the lipid-lowering drugs in women during that initial transition phase.

SPEAKER_00 10:56

Ah, but once those hormonal protections wane or the disease pathology overwhelms them in later stages, the benefits of the drugs become universal.

SPEAKER_01 11:05

That's exactly what the data suggests.

SPEAKER_00 11:06

Okay, so we've established the demographics, and the data clearly shows these drugs are buying people crucial years of independence.

SPEAKER_01 11:12

Yes, they absolutely are.

SPEAKER_00 11:13

Which brings us to the most

Autopsies Reveal A Shocking Paradox

SPEAKER_00 11:15

logical assumption. If these patients are thinking clearer, functioning better, and surviving longer, these cholesterol drugs must be actively clearing the Alzheimer's pathology out of their brains.

SPEAKER_01 11:27

It is the most logical assumption to make. You'd think a slower cognitive decline should equal a cleaner brain.

SPEAKER_00 11:33

We would expect their brains to look healthier. But the postmortem autopsy data reveals a stunning twist.

SPEAKER_01 11:39

It really is a profound divergence between clinical symptoms and physical pathology.

SPEAKER_00 11:45

Because nearly a quarter of the thousands of participants in this study eventually underwent brain autopsies after they passed away.

SPEAKER_01 11:51

Right.

SPEAKER_00 11:52

And the researchers meticulously measured the physical hallmarks of Alzheimer's disease. They measured the break staging, which you know maps how toxic tau tangles spread through the brain's memory centers.

SPEAKER_01 12:03

They also measured hippocampal atrophy, which is the literal shrinkage of the brain tissue.

SPEAKER_00 12:08

And they measured tau levels in the cerebrospinal fluid.

SPEAKER_01 12:11

And across every single one of those physical metrics, there was zero statistical difference between the people who took the cholesterol drugs and the people who didn't.

SPEAKER_00 12:18

Wait, really? Zero difference.

SPEAKER_01 12:20

Zero.

SPEAKER_00 12:21

Here's where it gets really interesting, because this completely fractures the traditional model of Alzheimer's we've been taught.

SPEAKER_01 12:28

It absolutely does.

SPEAKER_00 12:29

You're telling me the patients taking the medication navigated their daily lives better and retained their cognitive faculties longer. But their physical brains were just as ravaged by tautangles and tissue loss as the patients who suffered rapid, severe dementia.

SPEAKER_01 12:44

Yes. Their brains had the exact same level of physical Alzheimer's disease. The physical damage was virtually identical.

SPEAKER_00 12:52

That is wild. It's like looking at two houses that endure the exact same devastating fire.

SPEAKER_01 12:58

Oh, that's a good way to picture it.

SPEAKER_00 12:59

You know, the structural damage to the wood, the intense heat, the burnt foundation, it's all identical.

SPEAKER_01 13:04

Right.

SPEAKER_00 13:04

But somehow, one house stays standing and habitable for years while the other one instantly collapses into ash.

SPEAKER_01 13:10

Which brings us to the concept of systemic resilience.

SPEAKER_00 13:13

Systemic resilience.

SPEAKER_01 13:14

Yes. The traditional medical model has largely viewed Alzheimer's through a singular lens, assuming that amyloid plaques and tau tangles directly and exclusively equal memory loss. Right. But this autopsy data proves that the clinical symptoms, the actual loss of memory and daily function, are not just a strict one-to-one result of those physical tangles.

SPEAKER_00 13:36

So the tangles are a prerequisite, but they aren't the only driver of the decline.

SPEAKER_01 13:40

Aaron Powell Exactly. The physical pathology of Alzheimer's acts as a massive stressor, but the speed of the cognitive collapse is heavily aggravated by other systemic factors happening

Oxysterols And The Inflammation Pathway

SPEAKER_01 13:50

throughout the rest of the body.

SPEAKER_00 13:51

Factors that the lipid-lowering drugs are actively fixing.

SPEAKER_01 13:55

Yes, mitigating.

SPEAKER_00 13:56

But if the cholesterol drugs aren't scrubbing the tautangles out of the brain directly, how exactly are they keeping the house standing? What is the actual mechanism providing that resilience?

SPEAKER_01 14:07

Well, the study highlights a dual drivers concept of neurodegeneration.

SPEAKER_00 14:12

Dual drivers.

SPEAKER_01 14:12

Right. Lipid lowering regimens, particularly statins, do much more than just lower numbers on a cholesterol test. They provide profound vascular stabilization.

SPEAKER_00 14:21

Oh, like improving the actual plumbing.

SPEAKER_01 14:23

Exactly. They improve endothelial function, which is the health of the inner lining of your blood vessels.

SPEAKER_00 14:28

Aaron Powell And better blood vessels mean a more consistent, stable supply of oxygen and nutrients to the brain tissue, preventing the microoschemia that normally accelerates cognitive decline.

SPEAKER_01 14:38

Aaron Powell That's a huge part of it. But in addition to vascular health, these drugs trigger widespread anti-inflammatory effects. Okay. And the most critical mechanism detailed in the study revolves around cholesterol oxidation products.

SPEAKER_00 14:51

Aaron Powell Specifically molecules known as oxysterols, right? Yes. Trevor Burrus, Let's focus on those oxysterols because this seems to be the linchpin of the entire phenomenon.

SPEAKER_01 14:58

Aaron Powell It really is. When you have high levels of peripheral cholesterol circulating in your bloodstream, your body metabolizes some of it into oxidation products.

SPEAKER_00 15:08

Okay.

SPEAKER_01 15:08

The two primary ones are 24OHC and 27OHC. Trevor Burrus, Jr.

SPEAKER_00 15:12

So high body cholesterol creates high levels of Tumel 7OHC in the blood.

SPEAKER_01 15:17

Right. And this raises an important question because the problem with 27OHC is its molecular structure.

SPEAKER_00 15:23

How so?

SPEAKER_01 15:24

Well, unlike standard cholesterol, which is largely blocked from entering the central nervous system, 27OHC has the ability to passively cross the blood-brain barrier.

SPEAKER_00 15:34

Oh, wow. So it bypasses the brain's security system entirely.

SPEAKER_01 15:38

It really does. And once 27OHC crosses that barrier and enters the brain, it binds to specific receptors on microglia.

SPEAKER_00 15:45

Microglia, those are the brain's resident immune cells, right?

SPEAKER_01 15:49

Exactly. Normally they act as the garbage collectors, clearing away cellular debris and keeping the environment healthy. Okay. But when 27OHC binds to them, it throws these immune cells into overdrive.

SPEAKER_00 16:02

Ah, so it shifts them from a protective cleanup crew into a toxic inflammatory state.

SPEAKER_01 16:07

Aaron Powell Yes. They begin releasing inflammatory cytokines. And this rampant neuroinflammation acts as an incredible accelerant for the existing Alzheimer's pathology.

SPEAKER_00 16:16

It's like throwing gasoline on that house fire.

SPEAKER_01 16:18

Exactly. The inflammation chemically promotes the rapid accumulation of toxic beta amyloid. It creates a hostile, acidic environment that makes the existing tau tangles infinitely more damaging to the surrounding neurons.

SPEAKER_00 16:31

So wait, let me clarify. It's not that the statins are acting like a brain scrubber. They are functioning as a border patrol.

SPEAKER_01 16:36

That is exactly what they're doing.

SPEAKER_00 16:38

So by aggressively lowering the cholesterol

The Next Wave Of Brain Drugs

SPEAKER_00 16:40

circulating in the body, the drugs drastically reduce the production of 27OHC.

SPEAKER_01 16:46

Yes.

SPEAKER_00 16:47

And with less of that toxic oxystol floating in the bloodstream, less of it crosses the blood-brain barrier to agitate the brain's immune system.

SPEAKER_01 16:54

They are essentially cutting off the toxic supply lines.

SPEAKER_00 16:58

Wow.

SPEAKER_01 16:58

By managing the lipid environment in the peripheral body, the drugs are literally starving the inflammatory process inside the brain.

SPEAKER_00 17:06

Even while the plaques is still there.

SPEAKER_01 17:08

Exactly. The physical plaques entangles are still forming as the autopsy showed. But without that secondary wave of inflammation fueled by 27 OHC, the brain tissue can tolerate the disease burden much longer.

SPEAKER_00 17:20

You know, it reframes our entire understanding of cognitive preservation.

SPEAKER_01 17:24

It really changes the whole paradigm.

SPEAKER_00 17:26

I mean, we started this deep dive exploring a cross-sectional illusion that suggested cholesterol medication might be harming cognition.

SPEAKER_01 17:33

Right, the confounding by indication.

SPEAKER_00 17:36

But by shifting to the longitudinal data, we uncovered a profound protective benefit that compounds over a decade, uniquely tailored by age and genetics. Absolutely. And I think the most revealing insight for you listening is that preserving human independence doesn't necessarily require a pristine, undamaged brain.

SPEAKER_01 17:54

No, it doesn't.

SPEAKER_00 17:55

Sometimes resilience simply requires cutting off the biological accelerants that make the damage catastrophic.

SPEAKER_01 18:02

Treating the whole biological system yields profound neurological benefits, even when the brain itself cannot be cured.

SPEAKER_00 18:10

Right.

SPEAKER_01 18:10

But you know, the mechanics of 270HC leave us with a deeply provocative question for the future of medicine.

SPEAKER_00 18:17

Oh. What's that?

SPEAKER_01 18:19

Well, we now know that standard cholesterol drugs dramatically slow cognitive decline purely by lowering peripheral cholesterol and preventing those oxystrols from crossing the blood-brain barrier. Trevor Burrus, Jr.

SPEAKER_00 18:30

Right. They're playing defense from the outside.

SPEAKER_01 18:32

Trevor Burrus, Jr. Exactly. So what happens when pharmaceutical companies leverage this data to design the next generation of lipid-lowering drugs?

SPEAKER_00 18:40

Oh, I see where you're going with this.

SPEAKER_01 18:41

Yeah. If a drug were engineered specifically to cross the blood-brain barrier itself, rather than just acting as a peripheral border patrol, the implications could be staggering.

SPEAKER_00 18:50

Aaron Powell So directly managing lipid metabolism and oxysterol production inside the brain's architecture.

SPEAKER_01 18:57

Exactly. Could that be the key to finally halting the progression of Alzheimer's entirely?

SPEAKER_00 19:03

That is an incredible thought to leave on. The medicine cabinet of the future might blur the lines between the cardiovascular and the neurological entirely.

SPEAKER_01 19:11

I think it inevitably will.

SPEAKER_00 19:13

Well, thank you for joining us on this deep dive. We encourage you to keep exploring the brilliant interconnected complexities of the human brain.